Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal EEG model detects antisense oligonucleotide treatment effect and increased UBE3A in Angelman syndrome

26 Apr 2022

Abstract excerpt

Abstract Angelman syndrome is a neurodevelopmental disorder caused by deficiency of the maternally inherited UBE3A gene in neurons. Antisense oligonucleotide therapies are under development to reinstate UBE3A protein production. Non-invasive biomarkers to detect target engagement and treatment response are needed to support clinical trials. Delta power measured in the scalp EEG is a reliable biomarker for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Genetic Syndromes and Imprinting
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35611307
DOI: 10.1093/braincomms/fcac106

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal EEG model detects antisense oligonucleotide treatment effect and increased UBE3A in Angelman syndromePMID 35611307Read ↗

Delta power robustly predicts cognitive function in Angelman syndromeSemantic proximity Read ↗

Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndromeSemantic proximity Read ↗

Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysisSemantic proximity Read ↗

Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS)Semantic proximity Read ↗

Development of an ASO therapy for Angelman syndrome by targeting an evolutionarily conserved region at the start of the <i>UBE3A-AS</i> transcriptSemantic proximity Read ↗

Therapies in preclinical and clinical development for Angelman syndromeSemantic proximity Read ↗

Early Developmental EEG and Seizure Phenotypes in a Full Gene Deletion of Ubiquitin Protein Ligase E3A Rat Model of Angelman Syndrome.Semantic proximity Read ↗

Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman SyndromeSemantic proximity Read ↗

Emerging Therapies and challenges for individuals with Angelman syndrome.Semantic proximity Read ↗

Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model.Semantic proximity Read ↗

Prenatal delivery of a therapeutic antisense oligonucleotide achieves broad biodistribution in the brain and ameliorates Angelman syndrome phenotype in mice.Semantic proximity Read ↗

Analysis of EEG patterns and genotypes in patients with Angelman syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.